BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NMT Medical, Inc (NMTI) And National Stroke Association Join Forces To Provide Education On PFO/Stroke Connection And Clinical Trials


10/19/2005 5:10:04 PM

BOSTON, Feb. 19 /PRNewswire-FirstCall/ -- NMT Medical, Inc. and the National Stroke Association (NSA) announced today that the two organizations have joined forces to promote the education and understanding of cryptogenic stroke and transient ischemic attack (TIA) in young patients. Cryptogenic stroke and TIA are of unknown origin and are in some cases associated with a common heart defect known as a patent foramen ovale, or PFO. Clinical trials are underway to study the best therapy for these patients.

The agreement was recently signed at the International Stroke Conference in San Diego, California and announced to the Executive Committee of the CLOSURE I clinical trial sponsored by NMT. The clinical trial is designed to evaluate the effectiveness of PFO closure using NMT's fourth generation STARFlex(R) technology versus drug therapy in certain stroke and TIA patients.

Anthony Furlan, M.D., the Section Head of Stroke and Neurologic Intensive Care, Medical Director, Cerebrovascular Center, Department of Neurology, Cleveland Clinic Foundation, and Primary Investigator of CLOSURE I, said, "The study is to determine the appropriate therapy for young cryptogenic stroke and TIA patients with a PFO. Is drug therapy or closing the PFO non-surgically the answer? We don't know. Educating young stroke patients and caregivers about the potential relationship between cryptogenic stroke and TIA and PFO is an important step forward in recruiting patients into this landmark study being conducted at 100 leading clinical centers in the United States."

Jim Baranski, Chief Executive Officer of NSA, said, "Our goal is to educate people on stroke; the symptoms, the potential causes and the available treatments. Providing information on cryptogenic stroke and TIA in young patients and on clinical trials is part of that goal. We are pleased to have NMT to support our education efforts."

John E. Ahern, President and Chief Executive Officer of NMT Medical, said, "The Company is committed to the stroke/PFO education process and we are pleased to have the resources of the NSA behind our commitment."

About The National Stroke Association

The National Stroke Association is a leading resource for information regarding stroke. NSA is a non-profit organization devoting 100 percent of its resources to stroke education through a variety of innovative and high impact programs. They provide education, services and community-based activities in prevention, treatment, rehabilitation and recovery.

About NMT Medical, Inc.

NMT Medical designs, develops and markets proprietary implant technologies that allow interventional cardiologists to treat cardiac sources of stroke through minimally invasive, catheter-based procedures. The Company also serves the pediatric interventional cardiologist with a broad range of cardiac septal repair implants delivered with nonsurgical catheter techniques. For more information about NMT Medical, please visit http://www.nmtmedical.com/.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements - including statements regarding the benefits of the education and outreach programs of the NSA on the patient enrollment process of NMT Medical's CLOSURE I study - involve known and unknown risks, uncertainties or other factors which may cause actual results, performance or achievements of NMT Medical to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. Factors that might cause such a difference include, but are not limited to, the risk factors discussed under the heading "Certain Factors That May Affect Future Results" included in Management's Discussion and Analysis of Financial Condition and Results of Operations in NMT Medical's Annual Report on Form 10-K for the year ended December 31, 2002, as amended, Quarterly Report on Form 10-Q for the period ended September 30, 2003 and subsequent filings with the U.S. Securities and Exchange Commission.

Contacts: At: NMT Medical, Inc. John E. Ahern President & Chief Executive Officer (617) 737-0930 jea@nmtmedical.com At: National Stroke Association Diane Mulligan-Fairfield Vice President of National Communications (303) 649-9299 dmulligan@stroke.org

NMT Medical, Inc.

CONTACT: John E. Ahern, President & Chief Executive Officer of NMTMedical, Inc., +1-617-737-0930, jea@nmtmedical.com; or Diane Mulligan-Fairfield, Vice President of National Communications of National StrokeAssociation, +1-303-649-9299, dmulligan@stroke.org



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES